Pfizer (PFE) Gains Strong Attention with New Rating from Cantor Fitzgerald

2 min read | October 23, 2024 11:41 AM PDT | By Team Kalkine Media

Google News:

Pfizer (PFE) Gains Strong Attention with New Rating from Cantor Fitzgerald — Image source: Shutterstock

Recent News

Why Moderna Is Capturing Market Attention Again?

Eli Lilly Coverage Buzz Keeps Healthcare Market Attention High

Sandisk Gains Attention As an AI-Driven Growth Stock

Why Micron Technology Is Benefiting From the AI Growth Wave?

Make Kalkine Media
My Trusted Source

Headlines

Pfizer receives positive recognition from Cantor Fitzgerald.

Multiple research firms adjust their outlook on Pfizer.

Analysts maintain favorable outlook for Pfizer’s future.

Pfizer (NYSE:PFE) has earned renewed attention after Cantor Fitzgerald reaffirmed its positive stance on the company, maintaining an "overweight" rating. The firm’s target price is set at $45, indicating optimism for the biopharmaceutical giant's potential growth in the near term. This rating highlights confidence in Pfizer’s advancements and market positioning.

Several other analysts have adjusted their views on Pfizer recently. Barclays increased its target price for the company, raising it slightly higher to reflect positive sentiment. Sanford C. Bernstein also took notice, initiating coverage on Pfizer, pointing to a stable outlook moving forward.

Wells Fargo and UBS Group have both increased their target prices for Pfizer, aligning their expectations for steady performance. Daiwa Capital Markets has gone a step further, upgrading Pfizer’s rating and projecting stronger outcomes for the company in the future. This collection of revised ratings signals growing confidence in Pfizer's ability to continue delivering value and maintaining its leadership within the biopharmaceutical industry.

At present, several analysts have given Pfizer favorable assessments, with some holding steady and others expressing stronger optimism about its direction. These updates suggest that Pfizer is positioned to sustain momentum, backed by consistent research and development, innovation, and its role in the healthcare landscape.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.